Drug intelligence / Profile preview

RVL-002

Development stage: Preclinical
Lead developer: Unravel Biosciences
Modality: Small Molecules

Overview

RVL-002 is a novel small molecule drug developed by Unravel Biosciences, targeting mitochondrial metabolism. It acts as a modulator of mitochondrial one-carbon (1C) metabolism and is being investigated for the treatment of nervous system diseases such as Rett syndrome, Fragile X syndrome, Leigh disease, nonalcoholic steatohepatitis (NASH), and obesity. The drug was identified using Unravel’s proprietary BioNAV™ platform[2][5][7].

Beyond the preview

Go deeper on RVL-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RVL-002.

Explore the full profile